Related Experiment Videos
[Neuroglycopenic syndromes in malignant tumors]
1Interné odd. A, KUNZ B. Bystrica.
Abstract:
Based on observations of five of own patients the author analyzes the causes of spontaneous hypoglycaemia in malignant tumours and assumes three mechanisms of development: 1. Metastatic affection of the liver reduces the reserves of homeostatically usable glycogen and can reduce also the amount of utilized insulin and glucagon, and this weakens the effectivity of contraregulating hormones. 2. In case of large mesenchymal tumours it is assumed that the cause of hypoglycaemia is the neoplastic formation of IGF II. For these hypoglycaemic states a low concentration of C-peptide, IRI (immunoreactive insulin), absence of response of growth hormone to hypoglycaemia, high IGF II in the tumour and plasma and high mRNA for IGF II in the tumour is typical. 3. In hypoglycaemic states with massive metastases in the liver, high IRI and C-peptide it is assumed the cause of hypoglycaemia is a metastatizing insular tumour or a nes.dioblastoma. In those instances concurrent peptic ulcers (gastrin production) are frequent.
Insights
Malignant tumors can cause spontaneous hypoglycemia through three main mechanisms: liver damage, IGF II production by mesenchymal tumors, or insular tumors/nesidioblastomas. These mechanisms impact glycogen, insulin, and growth hormone regulation.
Area of Science:
- Endocrinology
- Oncology
Background:
- Spontaneous hypoglycemia can be a rare but serious complication of malignancy.
- Understanding the underlying mechanisms is crucial for diagnosis and management.
Observation:
- Analysis of five patients with malignant tumors presenting with hypoglycemia.
- Observed varying clinical and biochemical profiles associated with different tumor types.
Findings:
- Mechanism 1: Liver metastases impair glycogenolysis and counter-regulatory hormone effectiveness.
- Mechanism 2: Large mesenchymal tumors associated with neoplastic Insulin-like Growth Factor II (IGF II) production, characterized by low C-peptide, immunoreactive insulin (IRI), blunted growth hormone response, and elevated IGF II.
- Mechanism 3: Metastatic insular tumors or nesidioblastomas causing hypoglycemia with high IRI and C-peptide, often accompanied by peptic ulcers due to gastrin production.
Implications:
- Differentiates hypoglycemia causes in cancer patients, aiding targeted treatment.
- Highlights the role of IGF II in tumor-induced hypoglycemia.
- Suggests specific tumor markers and clinical features for diagnosing the cause of hypoglycemia in malignancy.